The Mind Research Network/Lovelace Biomedical and Environmental Research Institute, Pete & Nancy Domenici Hall, Albuquerque, New Mexico, USA.
Lovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico, USA.
J Neurotrauma. 2021 Jul 15;38(14):1904-1917. doi: 10.1089/neu.2020.7148. Epub 2021 Jan 25.
There is not a single pharmacological agent with demonstrated therapeutic efficacy for traumatic brain injury (TBI). With recent legalization efforts and the growing popularity of medical cannabis, patients with TBI will inevitably consider medical cannabis as a treatment option. Pre-clinical TBI research suggests that cannabinoids have neuroprotective and psychotherapeutic properties. In contrast, recreational cannabis use has consistently shown to have detrimental effects. Our review identified a paucity of high-quality studies examining the beneficial and adverse effects of medical cannabis on TBI, with only a single phase III randomized control trial. However, observational studies demonstrate that TBI patients are using medical and recreational cannabis to treat their symptoms, highlighting inconsistencies between public policy, perception of potential efficacy, and the dearth of empirical evidence. We conclude that randomized controlled trials and prospective studies with appropriate control groups are necessary to fully understand the efficacy and potential adverse effects of medical cannabis for TBI.
目前没有一种药物被证实对创伤性脑损伤(TBI)具有治疗效果。随着最近的合法化努力和医用大麻的日益普及,TBI 患者将不可避免地将医用大麻视为一种治疗选择。TBI 的临床前研究表明,大麻素具有神经保护和心理治疗特性。相比之下,娱乐性大麻的使用则一直显示出有害影响。我们的综述发现,高质量研究探讨医用大麻对 TBI 的有益和不利影响的研究很少,仅有一项 III 期随机对照试验。然而,观察性研究表明,TBI 患者正在使用医用和娱乐用大麻来治疗他们的症状,这突显了公共政策、潜在疗效的认知和缺乏经验证据之间的不一致性。我们的结论是,有必要进行随机对照试验和前瞻性研究,并设立适当的对照组,以充分了解医用大麻治疗 TBI 的疗效和潜在的不良反应。